Robert A. Bradway

Type: Person
Name: Robert A. Bradway
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Why Amgen Stock Is A Long-Term Investment Opportunity

Summary Amgen has a top-quality pipeline that should sustain long-term growth. Amgen's restructuring plan will provide savings and will enable the company to focus on growth areas. Amgen is generating strong cash flows and returns value to its shareholders ... [Published Seeking Alpha - Aug 27 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Amgen's Phase III relapsed multiple myeloma trial meets primary endpoint

Amgen, a biotechnology company, and its subsidiary, Onyx Pharmaceuticals, Inc., have announced that a planned interim analysis demonstrated that the Phase III clinical trial, ASPIRE, or CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide ... [Published Individual.com - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 1 reports

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

By a News Reporter-Staff News Editor at Clinical Trials Week -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc. , announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, ... [Published 4 Traders - Aug 13 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Amgen Attains CEO Cancer Gold Standard Accreditation

The CEO Roundtable on Cancer reported that Amgen has been given CEO Cancer Gold Standard accreditation. The organization said that this achievement recognizes employers' commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging ... [Published Individual.com - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Amgen Achieves CEO Cancer Gold Standard Accreditation

Amgen, Inc. announced that it has achieved CEO Cancer Gold Standard™ accreditation, created by the CEO Roundtable on Cancer , a nonprofit organisation of CEOs.Commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early ... [Published Asian Hospital & Healthcare Management - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Amgen Receives CEO Cancer Gold Standard Accreditation

The CEO Roundtable on Cancer today announced that Amgen, Inc.,one of the world's leading biotechnology companies, has received CEOCancer Gold Standard ™ accreditation. This achievement recognizesemployers’ commitment to reducing cancer risk by promoting ... [Published CW 50 Detroit - Aug 11 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 3 reports

Amgen Announces Phase III Trial of Kyprolis Met Primary Endpoint

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment ... [Published PharmaceuticalProcessing - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Amgen to cut up to 3,000 jobs, most in U.S., close facilities

Amgen has announced a restructuring plan to invest in continuing innovation and the launch of its new pipeline molecules, while improving cost structure.Initial efforts include streamlining the organization, reducing layers of management, increasing managerial ... [Published Center Watch - Jul 31 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 2 reports

Amgen, Inc. (AMGN) Announces Revenue Growth And Profitability In The Second Quarter

Amgen, Inc. (NASDAQ : AMGN )   announced its second quarter financial results on July 29, 2014. Amgen’s total revenues increased by 11% on the year to $5.18 billion. Enbrel, Kyprolis, Prolia and XGEVA are the strongest performers among the Amgen, Inc. ... [Published InsiderMonkey.com - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 2 reports

Amgen closing Longmont, Boulder facilities

Local loss of 430 jobs will contribute to overall reduction of as many as 2,900 by end of 2015, most of those in U.S.Biotechnology firm Amgen announced Tuesday that it is closing its facilities in Colorado and Washington and reducing staff worldwide ... [Published Burlington Record - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Amgen to Lay off up to 2,900; 2Q Revenues up 11 Percent

Amgen reported that its total revenues increased 11 percent to $5,180 million, with 8 percent product sales growth driven by strong performance across the portfolio, particularly Enbrel (etanercept), Kyprolis (carfilzomib), Prolia (denosumab) and XGEVA ... [Published Pharmaceutical Manufacturing Magazine - Jul 30 2014]
Entities: Amgen Inc, Enbrel, Denosumab
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financial Results

/PRNewswire/ — Amgen (AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and ... [Published Jutia Group - Jul 25 2014]

More Content

All (20) | News (20) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Why Amgen Stock Is A Long-Term Investment Oppor... [Published Seeking Alpha - Aug 27 2014]
Amgen's Phase III relapsed multiple myeloma tri... [Published Individual.com - Aug 20 2014]
Amgen Attains CEO Cancer Gold Standard Accredit... [Published Individual.com - Aug 14 2014]
Amgen Announces Phase 3 ASPIRE Trial Of Kyproli... [Published 4 Traders - Aug 13 2014]
Amgen Achieves CEO Cancer Gold Standard Accredi... [Published Asian Hospital & Healthcare Management - Aug 12 2014]
Amgen Receives CEO Cancer Gold Standard Accredi... [Published CW 50 Detroit - Aug 11 2014]
Why Amgen Is Slimming Up [Published Seeking Alpha - Aug 05 2014]
Amgen Announces Phase III Trial of Kyprolis Met... [Published PharmaceuticalProcessing - Aug 04 2014]
UPDATE: Amgen Announces Phase 3 ASPIRE Trial of... [Published Benzinga.com - Aug 04 2014]
Amgen Announces Phase 3 ASPIRE Trial Of Kyproli... [Published Industrial Info Financials - Aug 04 2014]
Amgen to cut up to 3,000 jobs, most in U.S., cl... [Published Center Watch - Jul 31 2014]
Amgen, Inc. (AMGN) Announces Revenue Growth And... [Published InsiderMonkey.com - Jul 30 2014]
Amgen to Lay off up to 2,900; 2Q Revenues up 11... [Published Pharmaceutical Manufacturing Magazine - Jul 30 2014]
Amgen closing Longmont, Boulder facilities [Published Burlington Record - Jul 30 2014]
Amgen to lay off up to 2,900 workers and close ... [Published Los Angeles Times - Jul 29 2014]
Amgen closing Longmont, Boulder facilities [Published Boulder Daily Camera - Jul 29 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Jul 25 2014]
Amgen Announces Webcast of 2014 Second Quarter ... [Published Stockwatch - Jul 24 2014]
Amgen's net earnings dips by 25% to $1,073 mill... [Published PharmaBiz - Apr 23 2014]
Amgen net rises by 30% to $1,021 mn in Q4 [Published PharmaBiz - Jan 30 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.